Navigation Links
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Date:10/1/2007

s 301 and 302. Twelve weeks after completing a 48-week course of therapy, 80% of HBeAg- patients had undetectable HBV DNA.

Clevudine was generally safe and well-tolerated by patients with chronic HBV. Serious adverse events during treatment in Studies 301 and 302 and during follow-up indicated that a higher percentage of placebo-treated patients had seriously elevated liver enzyme levels. Otherwise, there was no meaningful difference between clevudine and placebo in the incidence of serious adverse events.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is in Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a Phase 1 clinical trial through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Hepsera is a registered trademark of Gilead Sciences, Inc.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looki
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2008)...RNewswire-FirstCall/ -- Eli Lilly and Company,(NY...g Application (sNDA) from,the U.S. Food and Drug ...Cl),for the management of chronic pain. Lilly pla...of 2009, adding data from a recently completed pos... knee. , The decision does not affect dulox...
(Date:11/25/2008)...prove recovery , , Audio and Web Video Reso... Mayo Clinic News Blog. Please see the bottom of t..., Minn., Nov. 25 A Mayo...don,t think they,re having a stroke -- and as a re...ion worsens. The findings appear in the current is...
(Date:11/25/2008)...25 Pharmacyclics, Inc.,... has completed a Phase 1,clinical trial with PCI-...molecule Factor VIIa inhibitor. The trial was cond...ate the safety and pharmacologic effect of,PCI-27... in a linear dose,response in the International N...
(Date:11/24/2008)...4 Leaders of Schering-Pl...update for investors on the company,s research pip...o that includes 46 new entities in clinical trials...studies. , , "Research and development is a...e continue our transformation," said Fred Hassan, ...
Breaking Medicine Technology:Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5LI COR Introduces the Odyssey 28R 29 Two Color NIR Fluorescent Protein Molecular Weight Marker 8270 1LI COR Introduces the Odyssey 28R 29 Two Color NIR Fluorescent Protein Molecular Weight Marker 8270 2Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 8265 1Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 8265 2Sysmex Announces Clinical Laboratory Software Name Change 8261 1Solos Endoscopy Inc in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 8256 1Solos Endoscopy Inc in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 8256 2
... PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 -...unced today that,majority-owned subsidiary Calando...eedings of the National Academy of Sciences,(PNAS)...ple,systemic dosing with Calando,s lead siRNA the...ary technologies in targeted,polymeric delivery sy...
... Iontophoretic Drug Delivery System, dermal patch ... and epinephrine (IDDS), SEATTLE, March 20, 2007...arma") Seattle, WA, a transdermal drug delivery co...ous Technologies, Inc.,("TTI"), Tokyo, Japan ann...nology, which administers lidocaine and epinephrin...
Other Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 2Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 3
(Date:12/1/2008)... nicotine use, personality illnesses common, study...ws) -- Psychiatric disorders are common among youn...ent, a new report shows. , To reach this findin...,000 respondents, aged 19 to 25, who took part in ...elated Conditions. , The study found that 45.8 ...
(Date:12/1/2008)...see problems with the agency,s goals, commitment a...hDay News) -- Responding to criticism that it has ...ply, the U.S. Food and Drug Administration release... consumers. , Among the most important changes ...r relationships with state and local health depart...
(Date:12/1/2008)...analysis of the National Cancer Institute,s cancer...der women experience delayed or incomplete radiati...and that this suboptimal care can lead to worse ou...ll Medical College and colleagues found that among...0 breast cancer registry patients aged 65 and olde...
(Date:12/1/2008)...ELLE, N.Y., Dec. 1 Due to the urge...n the field of AIDS/HIV research and clinical care...vide complimentary access to all archival online i...nd of December in honor of World AIDS Day. Free on...nd STDs ( www.liebertpub.com/apc ) and AIDS Re...
Breaking Medicine News(10 mins):Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2
...new head of the Ontario Medical Association has ma...t priority. // He has asked the provincial govern...nadian-trained doctors working in the US to come h...nine thousand physicians who were trained in Canad...
...among doctors working in the radiological departme...cher and assistant professor at the Department of ...and Medical Center has come up with a new techniqu...t would not obstruct their movement and would allo...
...lth service is losing more than ?50m because of pe...te years of similar complaint by NHS managers the ...sson from Hinchingbrooke Hospital in Huntingdon sa... do not turn up as they feel better while others f...
...shown that cutting back a few calories from our di...event certain age related changes in cells. // S...te on Aging have found that eating a little less f...a lifespan can reduce or even reverse aging-relate...
Other Medicine News:Health News:Ontario Medical Association Planning To Lure Back Expat Doctors 2Health News:Cut Calories to Age Gracefully 2Health News:Cut Calories to Age Gracefully 3
...se, stress . . . Theyre all factors that affect a ...ts difficult, and often overwhelming, to accuratel...ts even more difficult to evaluate these day-to-da...ider quickly so healthcare recommendations can be ...
...d for detecting trends and tracking patterns in gl...ldren/adolescents (aged 7 to 17) with diabetes. Pa...r with their children/adolescents. The G2 Biograph...ional blood glucose monitoring. Interpretation of ...
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction.
Mayo dissecting scissors with beveled blades.
Medicine Products: